// App-Quantinova.ai

: Clinical characteristics and outcomes of trial-ineligible patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving androgen receptor targeted (ART) therapy.

Researchers

Presenter

  • George Slade Mellgard

Principal Investigators

  • Stephen Mccroskery

  • Zakaria Chakrani

  • Nathaniel Saffran

  • Nicole Taylor

  • Bobby Chi-Hung Liaw

  • Matt D. Galsky

  • William K. Oh

  • Kai Tsao

  • Vaibhav G. Patel

Medical Centers

  • Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, Stamford, CT

  • Icahn School of Medicine at Mount Sinai, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved